CHI3L1 and metabolic dysfunction-associated steatohepatitis: Therefore, Chi3L1 gene is highly expressed in both human and murine liver with NAFLD/NASH histology and all three anti-Chi3L1 mAb proteins, to variable degrees, inhibit its function in vivo and substantially improve hepatic insulin resistance following 16 weeks of anti-Chi3L1 mAb treatment.